| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1073827 | Gaceta Sanitaria | 2011 | 7 Pages |
Abstract
Pneumococcal vaccination with Synflorix® in comparison with Prevenar13® in children aged less than 2 years old in Spain could achieve a higher number of QALYs and a substantial cost offset. Vaccination with Synflorix® would be a dominant strategy in terms of cost-effectiveness.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Raúl Morano, Ferrán Pérez, Max Brosa, Isabel Pérez Escolano,